经膀胱机器人辅助根治性前列腺切除术的初步经验与手术结局
本研究详细描述了使用da Vinci Si/Xi系统行经膀胱机器人辅助根治性前列腺切除术(RARP)的技术,并评估35例局限性前列腺癌患者的功能与肿瘤学结局。结果显示该术式术后尿控恢复良好,阳性手术切缘率为11.4%,随访至少12个月无生化复发。
要点
- 阳性手术切缘率为11.4%,术后病理分期以pT2为主。
- 随访至少12个月无生化复发,长期结局需进一步研究。
核心结论
- 经膀胱途径是RARP在特定患者中的有效替代方案,术后尿控前景良好。
研究设计与样本
- 单中心前瞻性病例系列,纳入35例局限性前列腺癌患者,随访至少12个月。
主要发现
- 平均手术时间150±35分钟,估计出血量100±45毫升。
- 阳性手术切缘4例(11.4%),随访至少12个月无生化复发。
- 术后6个月尿动力学最大尿流率中位数13.7 mL/s,膀胱容量370.2 mL,逼尿肌收缩力35.6 mmH2O。
关键数值与推荐
- 术前平均年龄63.4±8.1岁,BMI 28.6±5.3 kg/m2,tPSA 10.8±4.9 ng/mL,前列腺体积30.6±14.4 mL。
- 术前活检Gleason评分中位数6(IQR 6-7),IIEF-5评分中位数18(IQR 16-20)。
- 术后病理:pT2a 24例,pT2b 9例,pT2c 2例,Gleason评分中位数6(IQR 6-7)。
临床怎么用
- 经膀胱RARP可作为 selected 局限性前列腺癌患者的一种术式选择,尤其关注术后尿控恢复。
局限性
- 样本量小(35例),随访时间短(至少12个月),长期功能与肿瘤学结果需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe in detail the techniques for transvesical robot-assisted radical prostatectomy (RARP) using the da Vinci Si/Xi system (Intuitive Surgical, Sunnyvale, CA, USA) and to evaluate functional and oncological outcomes in 35 patients with prostate cancer. PATIENTS AND METHODS: Thirty-five patients with localized prostate cancer were enrolled for transvesical RARP. The patients' preoperative data (mean ± sd age 63.4 ± 8.1 years, body mass index 28.6 ± 5.3 kg/m2 , total prostate-specific antigen 10.8 ± 4.9 ng/mL and prostate volume 30.6 ± 14.4 mL, and median [interquartile range {IQR}] biopsy Gleason score 6 [6-7], and International Index of Erectile Function [IIEF]-5 score 18 [16-20]) were collected. Preoperative assessment revealed 28 cases of cT2a and seven cases of cT2b disease. All patients were continent preoperatively (defined as no pad required or one dry pad per day as a precaution). Surgical results and peri-operative complications were assessed. All patients were followed up for at least 12 months postoperatively. RESULTS: The mean operating time was 150 ± 35 min. Estimated blood loss was 100 ± 45 mL. Urinary infection was noted in one patient and managed with levofloxacin. Another patient complained of nocturia on postoperative day 14, which was relieved with solifenacin succinate. Urethral catheters were removed on postoperative day 7. Thirty-two patients achieved immediate urinary continence, with three patients returning to full continence on postoperative day 14. Postoperative pathology confirmed 24 pT2a cases, nine pT2b cases and two pT2c cases (median [IQR] Gleason score 6 [6-7]). Positive surgical margins were found in four patients (11.4%). No urethral stricture or urinary leakage was noted on urethrocystography taken 3 months after surgery. Urodynamic studies were performed preoperatively and 6 months after surgery: median (IQR) maximum urinary flow 12.2 (10.2-14.9) vs 13.7 (10.1-15.0) mL/s; bladder capacity 385.3 (351.3-410.2) vs 370.2 (330.1-395.4) mL; and voiding phase detrusor contractility 38.5 (27.8-42.3) vs 35.6 (28.3-41.3) mmH2 O, respectively. During a minimum of 12 months of follow-up, no biochemical recurrence was noted in any patient. The median (IQR) IIEF-5 score was 17 (16-19). CONCLUSIONS: The transvesical approach is a valid alternative to RARP in selected patients, providing promising postoperative urinary continence. Long-term functional and oncological results require further investigation.
引用
- Zhou X, Fu B, Zhang C, et al. Transvesical robot-assisted radical prostatectomy: initial experience and surgical outcomes. BJU Int. 2020. PMID: 32402143. doi:10.1111/bju.15111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。